Trade XOMA Corporation - XOMA CFD

Add to favourite

24.94

1.63%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.57

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

XOMA Corp ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	24.54
Open*	24.34
1-Year Change*	25.92%
Day's Range*	24.34 - 25.47
52 wk Range	13.48-23.51
Average Volume (10 days)	22.42K
Average Volume (3 months)	638.18K
Market Cap	219.42M
P/E Ratio	-100.00K
Shares Outstanding	11.49M
Revenue	4.41M
EPS	-2.81
Dividend (Yield %)	N/A
Beta	0.54
Next Earnings Date	Mar 7, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 19, 2024	24.94	0.61	2.51%	24.33	25.78	24.33
Apr 18, 2024	24.54	0.57	2.38%	23.97	25.22	23.97
Apr 17, 2024	24.03	0.06	0.25%	23.97	24.16	23.97
Apr 16, 2024	24.10	0.13	0.54%	23.97	24.10	23.97
Apr 15, 2024	24.30	-1.52	-5.89%	25.82	25.82	24.23
Apr 12, 2024	25.47	-0.60	-2.30%	26.07	26.67	25.17
Apr 11, 2024	25.92	0.20	0.78%	25.72	26.42	25.13
Apr 10, 2024	25.14	0.22	0.88%	24.92	25.17	24.92
Apr 9, 2024	25.35	0.52	2.09%	24.83	25.68	24.73
Apr 8, 2024	24.98	-0.33	-1.30%	25.31	25.67	24.64
Apr 5, 2024	25.26	0.59	2.39%	24.67	26.36	24.32
Apr 4, 2024	25.63	0.24	0.95%	25.39	25.72	24.32
Apr 3, 2024	25.80	-0.39	-1.49%	26.19	26.52	25.09
Apr 2, 2024	25.98	1.01	4.04%	24.97	26.47	24.79
Apr 1, 2024	25.19	1.84	7.88%	23.35	25.47	23.19
Mar 28, 2024	23.87	1.15	5.06%	22.72	24.18	22.72
Mar 27, 2024	23.19	0.22	0.96%	22.97	23.27	22.97
Mar 26, 2024	23.11	-0.66	-2.78%	23.77	23.77	23.10
Mar 25, 2024	24.04	-1.15	-4.57%	25.19	25.47	24.04
Mar 22, 2024	24.46	0.29	1.20%	24.17	25.42	24.17

XOMA Corporation Events

Time (UTC)	Country	Event
Tuesday, May 7, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 XOMA Corp Earnings Release Q1 2024 XOMA Corp Earnings Release Forecast - Previous -
Wednesday, May 15, 2024
Time (UTC) 16:00	Country US	Event XOMA Corp Annual Shareholders Meeting XOMA Corp Annual Shareholders Meeting Forecast - Previous -
Thursday, May 16, 2024
Time (UTC) 16:00	Country US	Event XOMA Corp Annual Shareholders Meeting XOMA Corp Annual Shareholders Meeting Forecast - Previous -
Tuesday, August 6, 2024
Time (UTC) 12:30	Country US	Event Q2 2024 XOMA Corp Earnings Release Q2 2024 XOMA Corp Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	6.027	38.16	29.385	18.37	5.299
Revenue	6.027	38.16	29.385	18.37	5.299
Total Operating Expense	23.441	20.931	16.969	22.255	22.156
Selling/General/Admin. Expenses, Total	23.191	20.46	16.799	21.002	18.563
Research & Development	0.153	0.171	0.17	1.253	1.682
Unusual Expense (Income)	0	0.3			1.911
Operating Income	-17.414	17.229	12.416	-3.885	-16.857
Interest Income (Expense), Net Non-Operating	0.255	-1.345	-0.832	-1.63	-1.465
Other, Net	0.04	0.005	0.213	3.533	4.881
Net Income Before Taxes	-17.119	15.889	11.797	-1.982	-13.441
Net Income After Taxes	-17.104	15.798	13.298	-1.982	-13.343
Net Income Before Extra. Items	-17.104	15.798	13.298	-1.982	-13.343
Net Income	-17.104	15.798	13.298	-1.982	-13.343
Income Available to Common Excl. Extra. Items	-22.576	7.968	9.01	-1.982	-13.343
Income Available to Common Incl. Extra. Items	-22.576	7.968	9.01	-1.982	-13.343
Diluted Net Income	-22.576	7.968	9.01	-1.982	-13.343
Diluted Weighted Average Shares	11.413	12.192	11.503	8.763	8.373
Diluted EPS Excluding Extraordinary Items	-1.9781	0.65354	0.78327	-0.22618	-1.59357
Diluted Normalized EPS	-1.9781	0.67801	0.78327	-0.22618	-1.44522
Total Adjustments to Net Income	-5.472	-7.83	-4.288		0
Dilution Adjustment					0
Depreciation / Amortization	0.097

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	1.658	0.437	1.486	0.451	0.983
Revenue	1.658	0.437	1.486	0.451	0.983
Total Operating Expense	7.615	10.607	7.696	4.823	5.75
Selling/General/Admin. Expenses, Total	5.777	6.196	7.571	4.794	5.71
Research & Development	0.039	0.054	0.028	0.029	0.04
Operating Income	-5.957	-10.17	-6.21	-4.372	-4.767
Interest Income (Expense), Net Non-Operating	0.557	0.357	0.214	0.194	0.058
Other, Net	0	0	0.005	0	0.039
Net Income Before Taxes	-5.4	-9.813	-5.991	-4.178	-4.67
Net Income After Taxes	-5.4	-9.813	-5.976	-4.178	-4.67
Net Income Before Extra. Items	-5.4	-9.813	-5.976	-4.178	-4.67
Net Income	-5.4	-9.813	-5.976	-4.178	-4.67
Total Adjustments to Net Income	-1.368	-1.368	-1.368	-1.368	-1.368
Income Available to Common Excl. Extra. Items	-6.768	-11.181	-7.344	-5.546	-6.038
Income Available to Common Incl. Extra. Items	-6.768	-11.181	-7.344	-5.546	-6.038
Diluted Net Income	-6.768	-11.181	-7.344	-5.546	-6.038
Diluted Weighted Average Shares	11.466	11.46	11.452	11.447	11.421
Diluted EPS Excluding Extraordinary Items	-0.59027	-0.97565	-0.64129	-0.48449	-0.52868
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.4529	-0.97565	-0.64129	-0.48449	-0.52868
Unusual Expense (Income)	1.575		0	0	0
Depreciation / Amortization	0.224	0.225	0.097
Other Operating Expenses, Total	0	4.132

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	61.253	96.973	88.065	59.973	47.626
Cash and Short Term Investments	58.161	94.102	84.222	56.688	45.78
Cash & Equivalents				56.688	45.78
Short Term Investments	0.335	0.774
Total Receivables, Net	2.367	0.209	1.789	2.933	1.468
Accounts Receivable - Trade, Net	0.001	0.209	0.263	2.933	1.468
Prepaid Expenses	0.725	0.613	0.443	0.352	0.378
Total Assets	140.382	166.562	125.285	95.724	63.785
Property/Plant/Equipment, Total - Net	0.036	0.213	0.38	0.544	0.059
Property/Plant/Equipment, Total - Gross					0.129
Accumulated Depreciation, Total					-0.07
Other Long Term Assets, Total	0.26	0.301	0.572	0.151	15.708
Total Current Liabilities	6.818	12.967	12.302	8.875	5.703
Accounts Payable	0.524	1.072	0.456	0.614	1.244
Accrued Expenses	2.952	0.72	0.821	1.108	2.298
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases		0	8.088	5.184	0.789
Other Current Liabilities, Total	3.342	11.175	2.937	1.969	1.372
Total Liabilities	16.368	24.686	38.861	51.736	45
Total Long Term Debt	0	0	12.764	27.093	21.69
Long Term Debt		0	12.764	27.093	21.69
Other Liabilities, Total	9.55	11.719	13.795	15.768	17.607
Total Equity	124.014	141.876	86.424	43.988	18.785
Common Stock	0.086	0.085	0.084	0.073	0.065
Additional Paid-In Capital	1306.27	1307.03	1267.38	1238.3	1211.12
Retained Earnings (Accumulated Deficit)	-1182.39	-1165.29	-1181.09	-1194.38	-1192.4
Total Liabilities & Shareholders’ Equity	140.382	166.562	125.285	95.724	63.785
Total Common Shares Outstanding	11.454	11.3153	11.2288	9.75858	8.69072
Long Term Investments		0	1.693	0.681	0.392
Note Receivable - Long Term	63.683	69.075	34.575	34.375
Cash	57.826	93.328	84.222
Other Current Assets, Total	0	2.049	1.611
Redeemable Preferred Stock	0.049	0.049	0.049
Total Preferred Shares Outstanding	0.9856	0.984	0.984
Intangibles, Net	15.15

	Sep 2023	Jun 2023	Mar 2023	Sep 2022
Total Current Assets	34.505	38.423	45.073	79.741
Cash and Short Term Investments	33.686	31.765	44.611	78.728
Cash	33.472	31.445	44.3	78.285
Total Receivables, Net	0.043	5.859	0.006	0.016
Accounts Receivable - Trade, Net	0.043	0.901	0.006	0.016
Prepaid Expenses	0.776	0.799	0.456	0.997
Other Current Assets, Total				0
Total Assets	124.094	125.661	133.664	146.131
Property/Plant/Equipment, Total - Net	0.005	0.022	0.073	0.081
Long Term Investments
Note Receivable - Long Term	74.696	72.232	73.333	66.049
Other Long Term Assets, Total	0.411	0.283	0.26	0.26
Total Current Liabilities	10.334	7.087	10.094	5.425
Accounts Payable	0.728	0.74	0.437	0.985
Accrued Expenses	2.16	1.95	6.196	1.293
Notes Payable/Short Term Debt	0	0	0	0
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total	7.446	4.397	3.461	3.147
Total Liabilities	18.13	15.537	19.138	15.806
Total Long Term Debt	0	0	0	0
Long Term Debt
Other Liabilities, Total	7.796	8.45	9.044	10.381
Total Equity	105.964	110.124	114.526	130.325
Redeemable Preferred Stock	0.049	0.049	0.049	0.049
Common Stock	0.086	0.086	0.086	0.086
Additional Paid-In Capital	1308.94	1307.59	1306.6	1306.61
Retained Earnings (Accumulated Deficit)	-1203.11	-1197.6	-1192.2	-1176.42
Total Liabilities & Shareholders’ Equity	124.094	125.661	133.664	146.131
Total Common Shares Outstanding	11.4728	11.4728	11.461	11.4508
Total Preferred Shares Outstanding	0.9856	0.9856	0.9856	0.984
Short Term Investments	0.214	0.32	0.311	0.443
Intangibles, Net	14.477	14.701	14.925

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-17.104	15.798	13.298	-1.982	-13.343
Cash From Operating Activities	-12.879	22.678	10.092	-0.285	-12.644
Cash From Operating Activities	0.007	0.007	0.022	0.025	0.03
Non-Cash Items	4.302	7.759	-3.415	5.767	3.651
Cash Interest Paid	0	0.311	0.692	0.558	0.081
Changes in Working Capital	-0.181	-0.886	0.187	-4.095	-2.982
Cash From Investing Activities	-20.221	-26.5	-0.209	-19.3	-15.006
Capital Expenditures	-15.247	0	-0.009	0	-0.006
Other Investing Cash Flow Items, Total	-4.974	-26.5	-0.2	-19.3	-15
Cash From Financing Activities	-4.451	12.835	19.793	30.493	29.939
Issuance (Retirement) of Stock, Net	2.419	41.584	29.45	22.539	22.915
Issuance (Retirement) of Debt, Net	0	-21.377	-5.33	8.547	7.487
Foreign Exchange Effects				0	0.02
Net Change in Cash	-37.551	9.013	29.676	10.908	2.309
Financing Cash Flow Items	-1.398	-3.873	-4.327	-0.593	-0.463
Cash Taxes Paid	0.076			0	1.637
Total Cash Dividends Paid	-5.472	-3.499
Amortization	0.097

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-9.813	-17.104	-11.128	-6.95	-2.28
Cash From Operating Activities	-4.924	-12.879	-8.989	-5.326	-1.009
Cash From Operating Activities	0.001	0.007	0.007	0.003	0.002
Non-Cash Items	1.764	4.302	3.162	2.235	1.332
Cash Interest Paid	0	0	0	0	0.095
Changes in Working Capital	2.899	-0.181	-1.03	-0.614	-0.063
Cash From Investing Activities	-7.234	-20.221	-4.974	-5	-5
Other Investing Cash Flow Items, Total	-7.234	-4.974	-4.974	-5	-5
Cash From Financing Activities	-1.368	-4.451	-3.129	-1.869	-0.735
Financing Cash Flow Items	0	-1.398	-1.398	-1.038	-0.973
Issuance (Retirement) of Stock, Net	0	2.419	2.373	1.905	1.606
Issuance (Retirement) of Debt, Net		0	0	0	0
Net Change in Cash	-13.526	-37.551	-17.092	-12.195	-6.744
Total Cash Dividends Paid	-1.368	-5.472	-4.104	-2.736	-1.368
Capital Expenditures		-15.247
Cash Taxes Paid		0.076	0.095	0.095
Amortization	0.225	0.097

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

XOMA Corporation Company profile

About XOMA Corp

XOMA Corporation (XOMA) is a biotechnology royalty aggregator. The Company's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The Company's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. The Company's royalty-aggregator business includes acquiring additional licenses to programs with third-party funding and has more than 70 assets. XOMA royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087); mezagitamab (TAK-079), iscalimab (CFZ533), and MK-4830.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, XOMA Corp revenues increased 30% to $38.2M. Net income applicable to common stockholders decreased 12% to $8M. Revenues reflect Europe segment increase of 40% to $35M, United States segment increase from $1.3M to $2.6M. Net income was offset by Stock-based Compensation in SGA increase of 56% to $6.2M (expense).

Equity composition

Common Stock $.0075 Par, 03/11, 46,666,666 auth., 29,510,963 issd. Insiders own 7.83%. PO: 4/91, 3.4M shs @ $26.50 by Alex. Brown& Sons. PO 6/01, 3M shs @ $15 by U.S. Bancorp Piper Jaffray. Series B Prfd. Stock $.05 Par, 8K auth., 2,959 issd. *1996, Co.'s 4% Conv. Subd. Debentures were conv. into 2M shs. of Common. 08/10, 1-for-15 reverse split.

Industry:

Bio Therapeutic Drugs

Suite 310
2200 Powell Street
EMERYVILLE
CALIFORNIA 94608
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024